Eli Lilly excels in capital allocation
Eli Lilly is leveraging massive GLP-1 cash flows to execute smart bolt-on acquisitions and build a long-term post-patent portfolio.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.